Silica Corpora is an innovative company founded in 2022, specializing in AI-based antibody design for therapeutic purposes. The company provides a powerful AI platform for designing antibody candidates for in-demand therapies, focusing on amino acid sequence-based drug discovery.

Silica Corpora's proprietary De Novo antibody therapy platform leverages AI, machine learning, and data analytics to optimize therapeutic antibodies targeting priority diseases. Their modular system includes the Generator, Discriminator, Optimizer, and Ep-Mapper modules, each contributing to efficient, precise, and controlled antibody design.

Their platform is designed to generate and improve antibody candidates through training AI models on amino acid sequences, enabling accurate prediction of antibody properties and epitope mapping without requiring extensive data sets or disrupting existing workflows.

Silica Corpora's mission is to develop advanced De Novo antibody discovery solutions that enhance the quality and cost-effectiveness of antibody therapeutics for diseases with high unmet needs.

The company was founded by Tim Ermak and Jaime Rosselló, with Anna-Catharina Krebs joining as Chief Scientific Officer in 2023. Silica Corpora partners with leading organizations such as Berkeley Skydeck, SIB, Charite, Google Cloud, and Fraunhofer Institute to drive innovation and expand impact.

Silica Corpora GmbH is located in Berlin, Germany. They maintain an active presence on social media platforms including Twitter (http://www.x.com/SilicaCorpora), LinkedIn (http://www.linkedin.com/company/silica-corpora/), and YouTube (https://www.youtube.com/@SILICACORPORA/featured). Their website offers further information and resources about their technology, team, careers, and partnerships.